摄入低聚半乳糖加重肠易激综合征症状可被α-半乳糖苷酶治疗减轻
这项随机双盲安慰剂对照交叉试验纳入31例符合罗马III标准且产氢的肠易激综合征患者,评估口服α-半乳糖苷酶与高低聚半乳糖食物同服是否减轻症状。高低聚半乳糖饮食使总体症状显著增加,21例出现低聚半乳糖敏感;全剂量酶降低总体症状和腹胀,呼气氢无差异。作者认为该策略可作为低FODMAP饮食的辅助治疗。
要点
- 高低聚半乳糖食物使肠易激综合征患者总体症状显著增加,21例出现低聚半乳糖敏感。
- 全剂量α-半乳糖苷酶降低低聚半乳糖敏感者的总体症状和腹胀。
- 呼气氢产量极少,安慰剂与全剂量酶之间无差异(P=0.597)。
核心结论
- 口服α-半乳糖苷酶与高低聚半乳糖食物同服可使低聚半乳糖敏感的肠易激综合征患者症状获得有临床意义的减轻。
- 作者认为该策略可转化为实践,作为低FODMAP饮食的辅助治疗以提高对高低聚半乳糖食物的耐受性。
研究设计与样本
- 随机、双盲、安慰剂对照、交叉试验。
- 招募符合罗马III标准且呼气试验产氢的肠易激综合征患者。
- 31例患者完成研究,其中腹泻型20例、便秘型4例、混合型7例。
- 参与者按随机顺序接受全剂量(300 GALU α-半乳糖苷酶)、半剂量(150 GALU α-半乳糖苷酶)和安慰剂(葡萄糖),各阶段间洗脱期≤14天。
- 先进行3天低FODMAP导入期,随后3天摄入提供的高低聚半乳糖饮食。
主要发现
- 添加高低聚半乳糖食物导致总体症状显著增加,21例患者出现低聚半乳糖敏感(总体症状增加>10 mm)。
- 在低聚半乳糖敏感者中,全剂量酶降低腹胀(20.5(9.5-42.0)vs 6.5(2.0-15.8);P=0.017)。
- 呼气氢产量极少,安慰剂与全剂量酶之间无差异(P=0.597)。
临床怎么用
- 作者认为口服α-半乳糖苷酶与高低聚半乳糖食物同服可作为低FODMAP饮食的辅助治疗,以提高低聚半乳糖敏感肠易激综合征患者对高低聚半乳糖食物的耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Galacto-oligosaccharides (GOS) are dietary FODMAPs (fermentable carbohydrates) associated with triggering gastrointestinal symptoms in patients with irritable bowel syndrome (IBS). This randomized, double-blind, placebo-controlled, cross-over trial aimed to assess whether oral α-galactosidase co-ingestion with foods high in GOS and low in other FODMAPs would reduce symptoms. METHODS: Patients meeting the Rome III criteria for IBS who were hydrogen-producers on breath testing were recruited. Participants were treated with full-dose (300 GALU (galactosidic units) α-galactosidase) and half-dose enzyme (150 GALU α-galactosidase), and placebo (glucose) in a random order with ≤14 days washout between arms. Following a 3-day low FODMAP run-in period, participants consumed provided diets high in GOS for a further 3-days. Gastrointestinal symptoms were measured daily using a 100 mm visual-analogue-scale, and breath samples taken hourly on the second last day with hydrogen content analysed as area-under-the-curve. RESULTS: Thirty-one patients with IBS (20 IBS-D, 4 IBS-C, 7 IBS-M) completed the study. The addition of high GOS foods resulted in a significant increase in overall symptoms with 21 patients exhibiting GOS-sensitivity (>10 mm increase for overall symptoms). Of those, full-dose enzyme reduced overall symptoms (median 24. 5(IQR 17.5-35.8) vs. 5.5(1.5-15.0) mm; P=0.006) and bloating (20.5(9.5-42.0) vs. 6.5(2.0-15.8); P=0.017). Breath hydrogen production was minimal with no differences seen between placebo and full-dose (P=0.597). CONCLUSIONS: Oral α-galactosidase taken with high GOS foods provides a clinically significant reduction in symptoms in GOS-sensitive individuals with IBS. This strategy can be translated into practice to improve tolerance to high GOS foods as an adjunct therapy to the low FODMAP diet.
引用
- Tuck CJ, Taylor KM, Gibson PR, et al. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. Am J Gastroenterol. 2017. PMID: 28809383. doi:10.1038/ajg.2017.245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。